Mapping AAV delivery: a new atlas for gene therapy precision
A newly developed AAV atlas provides a detailed map of viral tissue targeting.
A multidisciplinary team from Baylor College of Medicine (TX, USA), The Jackson Laboratory (ME, USA) and the University of Massachusetts Medical School (USA) has developed a comprehensive reference atlas that can be used to help researchers select the appropriate adeno-associated virus (AAVs) variant for their target organ.
The success of gene therapy depends on effectively and precisely delivering genetic material to the intended cells or tissues. AAVs are widely used as delivery vehicles due to their efficiency and favorable safety profile, however selecting the optimal AAV variant for a given organ or cell type remains a challenge.
To address, the team set out to develop a comprehensive reference atlas that provides researchers with detailed information on which AAVs target specific tissues, helping improve gene therapy precision and reduce off-target effects.
To generate the atlas, the researchers analyzed how 10 different AAV variants interacted with 22 tissues in mice, including both male and female subjects. Using fluorescent imaging, they mapped gene delivery efficiency at the cellular level, offering a high-resolution view of where each AAV delivered its genetic material.
Nanosensing platform to enhance quality control of viral vectors
Researchers have introduced an innovative nanosensing method to assess the properties of viral vectors.
The study also uncovered new insights into AAV biology, including findings that could have clinical significance. Notably, the team identified some unique properties of AAV4. Unlike most AAVs, which primarily target the liver, AAV4 showed a strong preference for endothelial cells in blood vessels and beta cells in the pancreas. This ability to target vascular tissues suggests that AAV4 could be a promising candidate for gene therapies targeting vascular tissues, an area where past efforts have struggled. Additionally, its affinity for pancreatic beta cells opens possibilities for treating diabetes.
“We hope that this resource, which is publicly available here, will help researchers engineer better gene therapy vectors for human conditions,” said corresponding author William Lagor (Baylor College of Medicine). “This will be useful across many disciplines which rely on AAV vectors for gene delivery in basic research. It will also make preclinical gene therapy studies in mice more efficient and reproducible, given that a lot of the homework on the best AAV for a given cell type has already been done.”